Cancer Vaccine Cuts Melanoma Return by 49% After 5 Years

For melanoma patients facing surgery, the question that haunts them most is simple: will it come back? Now, researchers at NYU Langone Health have an answer that's changing lives.

A new study shows that combining a personalized cancer vaccine called intismeran with standard immunotherapy cut the risk of melanoma returning by 49% five years after surgery. Even more remarkable: 68.8% of patients who received the combination remained completely cancer-free.

The trial followed 157 melanoma patients after their tumors were surgically removed. Half received both the vaccine and pembrolizumab (a widely used immunotherapy drug), while the others received only the immunotherapy. The difference was striking. Only 49.1% of patients who got immunotherapy alone stayed cancer-free.

Dr. Janice Mehnert, the study's lead researcher, explained that intismeran works differently than traditional treatments. The vaccine is personalized for each patient using information from their specific tumor. It teaches the immune system to recognize 34 unique abnormal proteins that cancer cells make, then hunts down any melanoma cells trying to regrow or spread.

The combination therapy also reduced the risk of cancer spreading to other parts of the body by 59%. Overall survival rates told an even more hopeful story: 92.2% of vaccine patients were alive after five years, compared to 71.3% in the immunotherapy-only group.

Side effects were manageable. Most patients experienced fatigue, pain at injection sites, and chills. Seven patients in each group died during the study, mostly from cancer.

The vaccine uses messenger RNA technology, the same approach that proved successful in COVID-19 vaccines. Because melanoma cells are known for evading the immune system and becoming resistant to treatment, researchers believed adding a personalized vaccine could make the difference. They were right.

Why This Inspires

This isn't just about melanoma. The success of intismeran opens doors for treating other cancers with high mutation rates that have been notoriously difficult to target. Researchers are already testing the vaccine for lung cancer and other forms of the disease.

About 112,000 Americans will be diagnosed with melanoma this year. While melanoma deaths have dropped significantly in the past decade thanks to treatment advances, this vaccine combination represents the next leap forward. It transforms cancer treatment from one-size-fits-all to truly personalized medicine.

A phase 3 trial is already underway to confirm these results in a larger group of patients. For the thousands of people diagnosed with melanoma each year, this research offers something precious: the real possibility of staying cancer-free.